Showing 291-300 of 739 results for "".
- CareCredit Hosts Free Webinar on How to Host Successful Patient Eventshttps://practicaldermatology.com/news/carecredit-hosts-free-webinar-on-how-to-host-successful-patients-events/2458975/CareCredit will be sponsoring a free webinar to all aesthetic providers on how to host successful patient events. The webinar, How to Host Events That Bring Real Results: The Dos, Don’ts, and Definites, will be presented by Karen Zupko, President of Karen Zupko & Associate
- Three New CeraVe Baby Products Awarded National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/three-new-cerave-baby-products-awarded-national-eczema-association-seal-of-acceptance/2458995/Valeant Pharmaceuticals North America LLC is pleased to announce today that all three products in its newest product line, CeraVe® Baby, have been awarded the National Eczema Association (NEA) Seal of Acceptance™, which maintains rigorous standards for approval. Products include Ce
- FDA Clears New 532 nm Laser Delivery System for PicoSure from Cynosurehttps://practicaldermatology.com/news/fda-clears-new-532-nm-laser-delivery-system-for-picosure-from-cynosure/2459001/Cynosure, Inc. received FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure®, creating a powerful, dual-wavelength laser system for removing tattoos of all colors in fewer treatments. PicoSure is widely recognized for its technology
- Cosmederm Bioscience Introduces Steve Massah as New Chief Operating Officerhttps://practicaldermatology.com/news/cosmederm-bioscience-introduces-steve-massah-as-new-chief-operating-officer/2459004/Cosmederm Bioscience has hired Steve Massah as its new Chief Operating Officer. As COO, Massah will provide strategic and tactical leadership, and management of manufacturing, product development, quality and product shipment and logistics. His work will ensure compliance with all government regu
- The Cetaphil Brand Launches New Cetaphil Baby Linehttps://practicaldermatology.com/news/the-cetaphil-brand-launches-new-cetaphil-baby-line/2459050/Galderma Laboratories, L.P., makers of Cetaphil, launched Cetaphil Baby, a line designed with babies and parents in mind. Cetaphil Baby is formulated with ingredients like organic calendula, almond oil and sunflower oil to soothe sensitive and irritated skin. All Cetaphil Baby products are
- The American Med Spa Association Launches a New Comprehensive Websitehttps://practicaldermatology.com/news/20140821-the_american_med_spa_association_launches_a_new_comprehensive_website/2459138/The American Med Spa Association launched a new user-friendly website it says will address all industry needs. The new user-friendly website features a more accessible format for members to obtain up to date information on their state's rules and regulations within the medical spa indust
- Regeneron and Sanofi Announce Positive Results from Phase IIb Study of Dupilumab for Atopic Dermatitishttps://practicaldermatology.com/news/20140715-regeneron_and_sanofi_announce_positive_results_from_phase_iib_study_of_dupilumab_for_atopic_dermatitis/2459168/Regeneron Pharmaceuticals, Inc. and Sanofi announced positive results from a Phase IIb dose-ranging study of dupilumab for moderate to severe atopic dermatitis. All doses of dupilumab met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scor
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Valeant Pharmaceuticals Announces Planned Management Departurehttps://practicaldermatology.com/news/20140616-valeant_pharmaceuticals_announces_planned_management_departure/2459206/Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that Ryan Weldon, Valeant's Executive Vice President and Company Group Chairman, will be leaving the Company following the divestiture of all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport ow
- Valeant Pharmaceuticals To Sell Filler And Toxin Assets To Nestle For $1.4 Billionhttps://practicaldermatology.com/news/20140528-valeant_pharmaceuticals_to_sell_filler_and_toxin_assets_to_nestle_for_14_billion/2459228/Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it has entered into an agreement with Nestle S.A. to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4 billion in cash. Nestle expects to complete its acquis